Global Markets
Novo Nordisk (NOVOB DC) says the European Commission has granted marketing authorisation for FREHEMGO (denecimig) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A
ORIGINAL · NewsquawkNovo Nordisk (NOVOB DC) says the European Commission has granted marketing authorisation for FREHEMGO (denecimig) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A
StockNow breaking-news AI analysis
Novo Nordisk says the European Commission authorised FREHEMGO for haemophilia A prophylaxis, following a November 9 report that the EU filing was under review.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.